Last updated: June 8, 2026
Lumakras (sotorasib) supply is concentrated around Amgen’s vertically managed program with external manufacturing and sourcing for drug substance (API) and finished dosage forms (film-coated tablets). The supplier landscape is shaped by (1) regulatory-quality manufacturing for FDA approval and ongoing cGMP supply, (2) patent-controlled manufacturing methods and formulations, and (3) global sourcing for commercial volume and pipeline-stage scale-up.
Who supplies Lumakras (sotorasib) drug substance (API)?
The drug substance supply for lumakras is handled through cGMP-qualified manufacturers under Amgen’s sourcing framework for commercialization and lifecycle scale. For business planning, contract manufacturing risk is driven by long-lead qualifications for API bulk, impurity control, and validated polymorph or synthetic route parameters that must match the FDA-approved manufacturing definition.
What API manufacturing vendors are linked to sotorasib commercial supply?
The supplier set is defined by Amgen’s commercial drug substance supply chain for sotorasib, including:
- cGMP API producers operating under DMF or referenced documentation for sotorasib intermediates and final API
- qualified backup API sources used to mitigate production disruptions and market demand surges
Who manufactures Lumakras finished tablets (drug product)?
Lumakras is marketed as oral tablets. Finished-dose manufacturing typically requires:
- validated tablet compression and coating processes
- controlled granulation, mixing uniformity, and dissolution performance
- packaging system qualification for stability and desiccant control where applicable
What contract manufacturers make Lumakras tablets?
Finished product is made by one or more cGMP drug product manufacturers used by Amgen to support commercial packaging and global distribution. Supplier selection is constrained by:
- batch record compatibility with the registered formulation
- coating thickness and dissolution equivalence to the clinical and commercial reference lots
- stability program responsibilities (including ongoing ICH storage conditions)
How do Amgen’s supplier contracts affect availability of Lumakras?
Supply continuity for lumakras is a function of cGMP capacity and supply agreements that control:
- change control thresholds for manufacturing site transfers or process modifications
- intermediate and API supply continuity during tech transfer
- validation timelines for any site change that could require prior regulatory notification or update filings
Which parts of the supply chain create bottlenecks?
Operational bottlenecks most often involve:
- API intermediates with longer synthesis lead time
- specialized reagents or catalysts with limited qualified suppliers
- coating and tablet finishing capacity during demand spikes
What packaging and distribution suppliers support Lumakras in the US and abroad?
Commercial distribution for tablets involves secondary packaging and logistics partners used by Amgen or its affiliates:
- packaging line qualification for label, bottle, and carton configurations used in US distribution
- global warehousing and cold-chain exclusion (oral solid dose typically ships at controlled ambient ranges, but stability requirements govern distribution windows)
Do packaging suppliers matter for regulatory compliance?
Yes. Packaging changes can require stability comparisons and sometimes updates to labeling or distribution control. Packaging vendors are selected to maintain:
- correct printed lot coding and serialization (where used)
- oxygen/moisture protection via container closure system performance
Who supplies excipients and key tablet components for Lumakras?
For oral tablets, excipients and functional components are sourced under quality systems tied to:
- regulatory specifications
- supplier traceability and change notification obligations
- particle size and water content controls that affect dissolution and manufacturability
What excipient categories are most relevant for sotorasib tablets?
Supplier categories typically include:
- film-coating polymers/plasticizers
- fillers and binders used in tablet matrices
- disintegrants and lubricants controlling breakup and flow
(Exact supplier names and specific component vendor identifications are typically embedded in DMF/excipient documentation, vendor qualification packages, and batch release records rather than public-facing disclosures.)
Which suppliers are relevant to biosimilar or generic entry risks for sotorasib?
Lumakras is a small-molecule oncology drug, not a biologic. Competitive risk for “generic entry” generally turns on:
- ANDA manufacturing that is able to reproduce the registered manufacturing process parameters
- bioequivalence and dissolution comparability that can be constrained by formulation or polymorphic behavior
- ability to source API at scale with controlled impurities
How do manufacturing suppliers change Paragraph IV or generic timelines?
Even when IP barriers fall, generic entry depends on:
- API sourcing or internal synthesis readiness
- completion of method validation for the ANDA commercial process
- ability to scale without changes that trigger regulatory rework
What supply-chain due diligence should be performed for Lumakras licensing or procurement?
For procurement, licensing, or litigation readiness, supplier due diligence typically targets:
- site qualification status (FDA inspection history and cGMP compliance record)
- DMF linkage and referenced master file status for key intermediates and API
- change-control history for any process steps tied to product quality attributes
- documented stability and analytical method transfer readiness
How to map supplier risk for tablets vs API
Tablet manufacturing is sensitive to formulation uniformity and coating control. API production is sensitive to synthesis route consistency, impurity profile, and batch-to-batch reproducibility. Any supplier substitution increases the risk of:
- analytical requalification needs
- dissolution profile shifts
- additional stability time or comparability studies
Key Takeaways
- Lumakras supply is concentrated around Amgen’s controlled sourcing for both sotorasib API and finished tablet drug product.
- API and tablet manufacturing are cGMP-constrained by impurity control, dissolution performance, and validated process definitions.
- Supplier substitution risk is primarily driven by tech transfer complexity, analytical comparability, and stability requirements for oral solid dose manufacturing.
- For commercial planning and competitive scenario modeling, map dependencies across API intermediates, finished-dose coating capacity, and packaging system qualification.
FAQs
- Which cGMP sites are authorized for sotorasib drug substance and tablets?
- How long does it typically take to qualify a new sotorasib API supplier for an ANDA commercial process?
- What manufacturing changes are most likely to require regulatory reporting for Lumakras tablets?
- What excipient specifications most affect dissolution and batch release for film-coated sotorasib tablets?
- How does API impurity control influence stability and release for sotorasib-containing oral tablets?
References
(No sources were provided in the prompt.)
